Abstract For advanced pulmonary metastases or melanoma, radiotherapy combined with immune checkpoint inhibitor can block the immunosuppression pathway, enhance the antitumor immune response, and significantly improve survival. Stereotactic body radiation therapy (SBRT) delivers a large dose of radiation to the tumor target with high precision while sparing irradiation of the surrounding normal tissues. It is suggested that SBRT could be the most appropriate radiotherapy modality to be combined with immunotherapy since it induces the expression of a series of cytokines and immune molecules and is more likely to cause intense immune response and exert an abscopal effect than conventional radiotherapy. Previous studies have explored that total dose and fractionation seem to be important parameters for determining the immune response;the timing of radiation with immunotherapy significantly influences the outcome, and tumor infiltrating lymphocytes, the expression level of programmed death-ligand 1, and mismatch repair defect may be important predicators of the outcome. With appropriate radiotherapy dose and fractionation, the optimal timing of radiation with immunotherapy, and effective predictive markers, a combination of SBRT and immunotherapy may eliminate advanced malignancies while activating the systemic immune response to exert an abscopal effect.
Fund:CSCO-Cancer Research Fund Merck(Y-MX2016-063)
Cite this article:
Lu Yi,Huang Minjie,Qiu Jianbo et al. Progress in stereotactic body radiation therapy combined with immunotherapy for advanced malignancies[J]. Chinese Journal of Radiation Oncology, 2017, 26(10): 1214-1217.
Lu Yi,Huang Minjie,Qiu Jianbo et al. Progress in stereotactic body radiation therapy combined with immunotherapy for advanced malignancies[J]. Chinese Journal of Radiation Oncology, 2017, 26(10): 1214-1217.
[1] Green DR,Ferguson T,Zitvogel L,et al. Immunogenic and tolerogenic cell death[J].Nat Rev Immunol,2009,9(5):353-363.DOI:10.1038/nri2545. [2] Casares N,Pequignot MO,Tesniere A,et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death[J].J Exp Med,2005,202(12):1691-1701.DOI:10.1084/jem.20050915 [3] Apetoh L,Ghiringhelli F,Tesniere A,et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy[J].Nat Med,2007,13(9):1050-1059.DOI:10.1038/nm1622 [4] Bayer C,Liebhardt ME,Schmid TE,et al. Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models[J].Int J Radiat Oncol Biol Phys,2014,88(3):694-700.DOI:10.1016/j.ijrobp.2013.11.008. [5] Reynders K,Illidge T,Siva S,et al. The abscopal effect of local radiotherapy:using immunotherapy to make a rare event clinically relevant[J].Cancer Treat Rev,2015,41(6):503-510.DOI:10.1016/j.ctrv.2015.03.011. [6] Schaue D,Ratikan JA,Iwamoto KS,et al. Maximizing tumor immunity with fractionated radiation[J].Int J Radiat Oncol Biol Phys,2012,83(4):1306-1310.DOI:10.1016/j.ijrobp.2011.09.049 [7] Filatenkov A,Baker J,Mueller AM,et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions[J].Clin Cancer Res,2015,21(16):3727-3739.DOI:10.1158/1078-0432.CCR-14-2824. [8] Finkelstein SE,Timmerman R,McBride WH,et al. The confluence of stereotactic ablative radiotherapy and tumor immunology[J].Clin. Dev Immunol,2011,2011:439752.DOI:10.1155/2011/439752. [9] Garcia-Barros M,Paris F,Cordon-Cardo C,et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis[J].Science,2003:300(5622):1155-1159.DOI:10.1126/science.1082504 [10] Dewan MZ,Galloway AE,Kawashima N,et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J].Clin. Cancer Res,2009,15(17):5379-5388.DOI:10.1158/1078-0432.CCR-09-0265. [11] Diallo I,Haddy N,Adjadj E,et al. Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer[J].Int J Radiat Oncol Biol Phys,2009,74(3):876-883.DOI:10.1016/j.ijrobp.2009.01.040. [12] Dewan MZ,Galloway AE,Kawashima N,et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J].Clin Cancer Res,2009,15(17):5379-5388.DOI:10.1158/1078-0432.CCR-09-0265. [13] Wu L,Wu MO,Dela-Maza L,et al. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model[J].Oncotarget,2015,6(14):12468-12480.DOI:10.18632/oncotarget.3487 [14] Wolchok JD,Kluger H,Callahan MK,et al. Nivolumab plus ipilimumab in advanced melanoma[J].N Engl J Med,2013,369(2):122-133.DOI:10.1056/NEJMoa1302369. [15] Hodi FS,O’Day SJ,Mcdermott DF,et al. Improved survival with ipilimumab in patients with metastatic melanoma[J].N Engl J Med,2010,363(8):711-723.DOI:10.1056/NEJMoa1003466. [16] Robert C,Thomas L,Bondarenko I,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J].N Engl J Med,2011,364(26):2517-2526.DOI:10.1056/NEJMoa1104621. [17] Eggermont AM,Chiarion-Sileni V,Grob JJ,et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage Ⅲ melanoma (EORTC 18071):a randomised,double-blind,phase 3 trial[J].Lancet Oncol,2015, 16(5):522-530.DOI:10.1016/S1470-2045(15)70122-1. [18] Postow MA,Callahan MK,Barker CA,et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J].N Engl J Med,2012,366(10):925-931.DOI:10.1056/NEJMoa1112824. [19] Silk AW,Bassetti MF,West BT,et al. Ipilimumab and radiation therapy for melanoma brain metastases[J].Cancer Med,2013,2(6):899-906.DOI:10.1002/cam4.140. [20] Twyman-Saint VC,Rech AJ,Maity A,et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J].Nature,2015,520(7547):373-377.DOI:10.1038/ nature14292. [21] Kwon ED,Drake CG,Scher HI,et al. CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043):a multicentre,randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(7):700-712.DOI:10.1016/ S1470-2045(14)70189-5. [22] Dovedi SJ,Adlard AL,Lipowska-Bhalla G,et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J].Cancer Res,2014,74(19):5458-5468.DOI:10.1158/0008-5472.CAN-14-1258. [23] Deng L,Liang H,Burnette B,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J].J Clin Invest,2014,124(2):687-695.DOI:10.1172/JCI67313. [24] Kroon P,Gadiot J,Peeters M,et al. Concomitant targeting of programmed death-1(PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma[J].Cancer Immunol Immunother,2016,65(6):753-763.DOI:10.1007/s00262-016-1843-4. [25] Golden EB,Chhabra A,Chachoua A,et al. Local radiotherapy and granulocytemacrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours:a proof-ofprinciple trial[J].Lancet Oncol,2015, 16(7):795-803.DOI:10.1016/S1470-2045(15)00054-6. [26] Crittenden M,Kohrt H,Levy R,et al. Current clinical trials testing combinations of immunotherapy and radiation[J].Sem Radiat Oncol,2015,25(1):54-64.DOI:10.1016/j.semradonc.2014.07.003 [27] Golden EB,Formenti SC.Radiation therapy and immunotherapy:growing pains[J].Int J Radiat Oncol Biol Phys,2015,91(2):252-254.DOI:10.1016/j.ijrobp.2014.09.018. [28] Linn YC,Hui KM.Cytokine-induced NK-like T cells:from bench to bedside[J].J Biomed Biotechnol,2010,2010:435745.DOI:10.1155/2010/435745. [29] Wang YS,Yang GQ,Wang YY,et al. Early efficacy of stereotactic body radiation therapy combined with adoptive immunotherapy for advanced malignancies[J].Mol Clin Oncol,2013,1(5):925-929.DOI:10.3892/mco.2013.157. [30] Yokouchi H,Yamazaki K,Chamoto K,et al. Anti-OX-40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer[J].Cancer Sci,2008,99(2):361-367.DOI:10.1111/j.1349-7006.2007.00664.x. [31] Kovacsovics-Bankowski LC,Vercellini J,Crittenden M,et al. Phase Ⅰ/Ⅱ clinical trial of anti-OX-40,radiation and cyclophosphamide in patients with prostate cancer:immunological analysis[J].J Immunother Cancer,2013,1(suppl1):P255.DOI:10.1186/2051-1426-1-S1-P255. [32] Young KH,Baird JR,Savage T,et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy[J/OL].PLoS One,2016,11(6):e0157164.DOI:10.1371/journal.pone.0157164. [33] Strigari L,Mancuso M,Ubertini V,et al. Abscopal effect of radiation therapy:interplay between radiation dose and p53 status[J].Int J Radiat Biol,2014,90(3):248-255.DOI:10.3109/09553002.2014.874608. [34] Diamond J,Pilones K,Aryankalayil J,et al. Radiotherapy induces responsiveness of a resistant mammary carcinoma to PD-1 blockade[J].J Immunother Cancer,2014,2(Suppl 3):P159.DOI:10.1186/2051-1426-2-S3-P159. [35] Ku GY,Yuan J,Page DB,et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting:lymphocyte count after 2 doses correlates with survival[J].Cancer,2010,116(7):1767-1775.DOI:10.1002/cncr.24951. [36] El-Khoueiry AB,Melero I,Crocenzi TS,et al. Phase Ⅰ/Ⅱ safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC):CA209-040[J].ASCO,2015:33(18 Suppl):LBA101.DOI:10.1200/jco.2015.33.18_suppl.lba101. [37] Taube JM,Klein A,Brahmer JR,et al. Association of PD-1,PD-1 ligands,and other features of the tumor immune microenvironment with response to anti-PD-1 therapy[J].Clin Cancer Res,2014,20(19):5064-5074.DOI:10.1158/1078-0432.CCR-13-3271. [38] Tumeh PC,Harview CL,Yearley JH,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J].Nature,2014,515(7528):568-571.DOI:10.1038/nature13954. [39] Johnson DB,Lovly CM,Flavin M,et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies[J].Cancer Immunol Res,2015,3(3):288-295.DOI:10.1158/2326-6066.CIR-14-0207. [40] Leavy O.Immunotherapy:a triple blow for cancer[J].Nat Rev Cancer,2015,15(5):258-259.DOI:10.1038/nrc3946.
2017, Vol. 26 
